Robert Demeester, PA
Medical · Royal Oak, MINPI 1336461748
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 85.4% of it on its own, with 40 other manufacturers making up the rest. Among medical clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 161 payments — averaging $165.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$23K
- Genmab U.S., Inc.$860
- AbbVie$750
- Pharmacyclics LLC, An Abbvie Company$185
- Sobi, Inc$169
- Takeda Pharmaceuticals U.S.A., Inc.$132
- plus $2K from 35 others
What the payments were for
- Consulting fees$1,5196%
- Speaking & faculty fees$15,09557%
- Travel & lodging$6,44924%
- Food & beverage$3,56913%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 47 | $22,762 |
| Genmab U.S., Inc. | 3 | $860 |
| AbbVie | 1 | $750 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $185 |
| Sobi, Inc | 5 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $132 |
| Genentech USA, Inc. | 6 | $129 |
| Novartis | 7 | $122 |
| AstraZeneca(2 entities) | 5 | $109 |
| Eisai Inc. | 5 | $106 |
| Pfizer | 6 | $100 |
| GSK | 6 | $99 |
| Johnson & Johnson | 4 | $92 |
| Astellas Pharma US Inc | 5 | $85 |
| Merck | 4 | $83 |
| Daiichi Sankyo Inc. | 4 | $77 |
| Beigene USA, Inc. | 3 | $69 |
| Bayer | 3 | $64 |
| Servier Pharmaceuticals LLC | 3 | $54 |
| Seagen Inc. | 3 | $47 |
| Taiho Oncology, Inc. | 2 | $39 |
| Rigel Pharmaceuticals, Inc. | 2 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| EMD Serono, Inc. | 2 | $37 |
| Lilly USA, LLC | 2 | $36 |
| Amgen | 2 | $36 |
| Bristol Myers Squibb | 2 | $35 |
| Stemline Therapeutics Inc. | 2 | $31 |
| Emmaus Medical, Inc. | 2 | $29 |
| Acrotech Biopharma Inc. | 1 | $29 |
| Immunocore Limited | 1 | $26 |
| Pharmacosmos Therapeutics Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Sanofi | 1 | $20 |
| Secura Bio, Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Deciphera Pharmaceuticals Inc. | 1 | $14 |
| Morphosys, US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,647 in reported general payments places this provider in the 95th percentile of 755 medical providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical in Royal Oak
- Lauren WaltersRoyal Oak$7K
- Caleb YoungbloodBerkley$215K
- Steven StoneKalamazoo$200K
- Meredith KentGrand Rapids$192K
- Amber ShullNorton Shores$154K
- Jason EvansWaterford$104K
- James ToreySaint Clair Shores$56K
- David WilkinsMuskegon$41K
- Mark RosenBerkley$32K
- John BrabantDetroit$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.